BPC-157: A Preclinical Research Overview

Published: March 2026

BPC-157 (Stable Gastric Pentadecapeptide): Research Overview

Overview

BPC-157, formally designated the stable gastric pentadecapeptide, is a synthetic 15-amino acid sequence derived from a protein originally identified in human gastric juice. First characterized by researchers at the University of Zagreb in the 1990s, BPC-157 has since become one of the more extensively studied peptides in preclinical pharmacology. Its chemical stability under acidic conditions — unlike many biologically active peptides — has made it a practical subject for a wide range of in vitro and in vivo experimental models. The compound is also known under the research designation PL 14736.

The breadth of systems examined in published BPC-157 literature is notable. Peer-reviewed investigations have explored its interactions with gastrointestinal tissue, the musculoskeletal system, the central nervous system, vascular biology, and nitric oxide signaling pathways. The Zagreb research group, led by Predrag Sikiric, has published extensively in journals including Current Pharmaceutical Design, Frontiers in Pharmacology, and Pharmaceuticals (Basel), establishing a substantial body of preclinical literature spanning more than two decades.

BPC-157 entered Phase II clinical trials for inflammatory bowel disease under the designation PL 14736, providing early safety data in human subjects for topical application. The preponderance of research, however, remains in preclinical models, and the translation of these findings to human therapeutic contexts has not been established. All information presented here reflects published research literature and is intended solely for scientific reference.

Molecular Profile

Mechanism of Action

At the molecular level, BPC-157 has been investigated in relation to several intersecting signaling pathways. Research has focused considerably on its relationship with the nitric oxide (NO) system. Published studies suggest that BPC-157 may modulate NO synthesis and downstream signaling in a context-dependent manner — appearing to counteract both NO excess and NO deficiency in experimental models of vascular and gastrointestinal injury. Specifically, in vitro and rodent-model data indicate interactions involving endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) pathways, though the precise binding targets and upstream molecular triggers remain subjects of active investigation.

BPC-157 has also been examined in relation to growth factor signaling. Preclinical data indicate that the peptide may upregulate or interact with pathways associated with vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), and early growth response protein 1 (EGR-1). Studies have documented rapid induction of gene expression in wound tissue, suggesting a role in the early transcriptional response to injury at the cellular level. The peptide’s influence on FAK-paxillin signaling — a pathway involved in cell migration and adhesion — has been proposed as a mechanistic link to its observed effects on tissue organization in experimental models.

Additionally, published literature has examined BPC-157’s interactions with neurotransmitter systems in rodent models. Studies have explored its effects in the context of dopaminergic, serotonergic, GABAergic, and glutamatergic pathway perturbations. The compound does not fit the classical definition of a neurotransmitter or receptor agonist, yet preclinical data suggest it may modulate the functional consequences of receptor blockade or neurotransmitter depletion in experimental contexts. The mechanistic basis of this apparent pleiotropic activity is an open question in the published literature.

Key Areas of Investigation

Gastrointestinal Cytoprotection and Mucosal Integrity

The earliest and most extensive BPC-157 research has concerned gastrointestinal tissue. In vitro and rodent studies have examined the peptide’s effects on gastric mucosal injury induced by ethanol, NSAIDs, and stress. Park et al. (2020) reviewed evidence suggesting BPC-157 may stabilize intestinal permeability in models of NSAID-induced cytotoxicity, proposing a mechanism involving maintenance of tight junction integrity and enhancement of cellular cytoprotective responses. In this preclinical context, the peptide has been described as countering the mucosal barrier disruption associated with NSAID exposure, though clinical translation has not been established.

Separate lines of investigation have examined BPC-157 in models of fistula formation and inflammatory bowel disease. The Zagreb group has published extensively on the peptide’s effects in colitis models, esophageal injury, and anastomotic healing in rodents, consistently reporting accelerated tissue reorganization relative to untreated controls.

Musculoskeletal Soft Tissue Healing

A systematic review by Gwyer, Wragg, and Wilson (2019), published in Cell and Tissue Research, surveyed the available preclinical literature on BPC-157 and musculoskeletal soft tissue. The authors concluded that “all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects” in rodent models of tendon, ligament, and muscle injury. The review noted BPC-157 has been studied across multiple administration routes with comparable outcomes reported at nanogram-to-microgram doses, while emphasizing that efficacy in humans has not been confirmed.

Seiwerth et al. (2018) examined BPC-157 alongside standard angiogenic growth factors, reporting that the peptide demonstrated broader applicability across tissue types than isolated growth factors such as EGF or FGF in the same experimental frameworks. Myotendinous junction healing, bone-tendon interface remodeling, and muscle transection recovery have all been examined in the published record.

Muscle Biology and Neuromuscular Function

Staresinic et al. (2022) reviewed BPC-157’s investigated effects across striated, smooth, and cardiac muscle types in preclinical models. Studies included models of muscle transection, denervation atrophy, vascular occlusion-induced ischemia, and electrolyte disturbance. The authors reported BPC-157 administration in these rodent models was associated with preservation of muscle architecture and restoration of contractile function, with effective dosing noted in the picogram-to-nanogram range in some models. No lethal dose has been established in published toxicology studies.

Central Nervous System and Neurotransmitter Modulation

Vukojevic et al. (2022), writing in Neural Regeneration Research, reviewed BPC-157’s investigated CNS effects across stroke, traumatic brain injury, spinal cord compression, and neuropsychiatric models in rodents. The review described experimental findings in which BPC-157 administration was associated with partial restoration of motor and cognitive function in stroke models and with attenuation of drug-induced catalepsy in dopamine-perturbation models. The precise molecular targets remain incompletely characterized.

Sikiric et al. (2024) extended this line of inquiry, proposing that BPC-157’s interaction with dopamine, serotonin, glutamate, GABA, and adrenergic systems — as observed in preclinical models — may reflect a shared downstream pathway rather than direct receptor agonism. These mechanistic proposals remain hypotheses grounded in animal model data and have not been validated in human studies.

Vascular Biology and Angiogenesis

BPC-157 has been studied in relation to blood vessel formation and vascular repair in preclinical settings. Seiwerth et al. (2014) examined the peptide’s effects on vessel morphology and NO-related vascular signaling in rodent models, reporting that BPC-157 appeared to counteract both vasoconstrictive and vasodilatory extremes in experimental conditions. The proposed mechanism involves modulation of eNOS activity and interaction with the VEGF pathway. The clinical relevance of these vascular findings has not been established.

Key Published References

1. Sikiric P, Boban Blagaic A, Strbe S, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. PMID: 38675421
2. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654
3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID: 30915550
4. Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482–487. PMID: 34380875
5. Staresinic M, Japjec M, Vranes H, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. PMID: 36551977
6. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972–1989. PMID: 29998800
7. Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020;26(25):2971–2981. PMID: 32445447

Product Availability

BPC-157 (10 mg) is available for qualified researchers through White Market Peptides: BPC-157 10 mg — Research Grade.